Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

Eli Lilly and Co. is shelling out $1 billion to buy a Boston biotech known for genetic medicines for cardiovascular disease.

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.

Major global pharmaceutical companies traded lower in the premarket on Tuesday after President Donald Trump reiterated his ...

Chronic low back pain (CLBP) is a widespread and long-lasting condition defined by lower back pain that lasts for at least 12 weeks. The l ...